Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron? 

Executive Summary

Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26
Advertisement

Related Content

Pegasys Catching Up To PEG-Intron; Schering Admits “Complacency”
Pegasys Catching Up To PEG-Intron; Schering Admits “Complacency”
Schering Global Pharma President Cox To Tackle Flagging Allergy Sales
Schering Global Pharma President Cox To Tackle Flagging Allergy Sales
Schering PEG-Intron Supply Constraints Resolved; Earnings Forecast Cloudy
Schering PEG-Intron Supply Constraints Resolved; Earnings Forecast Cloudy
Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration
Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration
Roche Pegasys Has $291 WAC; Launch Includes 12 Weeks Of Free Samples
Schering PEG-Intron/Rebetol Wait List Patients To Receive Drug By April
Advertisement
UsernamePublicRestriction

Register

PS041366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel